Cancer Genetics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Cancer Genetics prevailing Real Value cannot be determined due to lack of data. The current price of Cancer Genetics is $0.0. Our model approximates the value of Cancer Genetics from analyzing the firm fundamentals such as Current Valuation of 18.73 M, return on equity of -68.71, and Profit Margin of (71.50) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Cancer Genetics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Cancer Genetics's current stock value. Our valuation model uses many indicators to compare Cancer Genetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cancer Genetics competition to find correlations between indicators driving Cancer Genetics's intrinsic value. More Info.Cancer Genetics is number one stock in price to earning category among related companies. It is number one stock in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cancer Genetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cancer Genetics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cancer Genetics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cancer Genetics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cancer Genetics and how it compares across the competition.
About Cancer Genetics Valuation
The delisted stock valuation mechanism determines the current worth of Cancer Genetics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Cancer Genetics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cancer Genetics based exclusively on its fundamental and basic technical indicators. By analyzing Cancer Genetics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cancer Genetics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cancer Genetics. We calculate exposure to Cancer Genetics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cancer Genetics's related companies.Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey. Cancer Genetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
8 Steps to conduct Cancer Genetics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cancer Genetics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cancer Genetics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cancer Genetics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cancer Genetics' revenue streams: Identify Cancer Genetics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cancer Genetics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cancer Genetics' growth potential: Evaluate Cancer Genetics' management, business model, and growth potential.
- Determine Cancer Genetics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cancer Genetics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cancer Genetics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Cancer Genetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Shares Percent Shares Out | 6.85% | |
| Revenue Growth | -24.20% | |
| Forward Price Earnings | -80.50 | |
| Float Shares | 3.51M | |
| Shares Short Prior Month | 1.15M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Cancer Stock
If you are still planning to invest in Cancer Genetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cancer Genetics' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |